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Lipid, fatty acid, carnitine‑ 
and choline derivative profiles 
in rheumatoid arthritis 
outpatients with different degrees 
of periodontal inflammation
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Johan G. Brun2,5 & Anne Isine Bolstad1*
Rheumatoid arthritis (RA) and periodontitis are chronic inflammatory diseases with several 
pathogenic pathways in common. Evidence supports an association between the diseases, but the 
exact underlying mechanisms behind the connection are still under investigation. Lipid, fatty acid (FA) 
and metabolic profile alterations have been associated with several chronic inflammatory diseases, 
including RA and periodontitis. Mitochondria have a central role in regulating cellular bioenergetic and 
whole‑body metabolic homeostasis, and mitochondrial dysfunction has been proposed as a possible 
link between the two disorders. The aim of this cross‑sectional study was to explore whole‑blood FA, 
serum lipid composition, and carnitine‑ and choline derivatives in 78 RA outpatients with different 
degrees of periodontal inflammation. The main findings were alterations in lipid, FA, and carnitine‑ 
and choline derivative profiles. More specifically, higher total FA and total cholesterol concentrations 
were found in active RA. Elevated phospholipid concentrations with concomitant lower choline, 
elevated medium‑chain acylcarnitines (MC‑AC), and decreased ratios of MC‑AC and long‑chain (LC)‑AC 
were associated with prednisolone medication. This may indicate an altered mitochondrial function 
in relation to the increased inflammatory status in RA disease. Our findings may support the need 
for interdisciplinary collaboration within the field of medicine and dentistry in patient stratification 
to improve personalized treatment. Longitudinal studies should be conducted to further assess the 
potential impact of mitochondrial dysfunction on RA and periodontitis.
Rheumatoid arthritis (RA) and periodontitis are chronic destructive inflammatory diseases that have complex 
multifactorial pathologic processes in  common1–4. Current evidence supports an association between periodon-
titis and RA, in a to date unidentified subgroup of patients, which most likely share genetic and environmental 
risk  factors5. Recent studies and meta-analysis report a higher occurrence of RA in patients with moderate to 
severe periodontitis compared to controls, and a higher prevalence of periodontitis and periodontal destruction 
in RA subjects compared to non-RA  subjects6–12. RA patients with persistent periodontal disease have shown less 
responsiveness to anti-tumor necrosis factor alpha (anti-TNFα) treatment, and it is reported that periodontal 
treatment may reduce RA disease  activity13,14. The relationship between RA and periodontitis has been attributed 
to unbalanced pro- and anti-inflammatory response and persistent inflammation along with structural damage. 
In both diseases, cells of the adaptive and innate immune system are found to promote the secretion of pro-
inflammatory cytokines, matrix metalloproteinases (MMP) and reactive oxygen species (ROS)15–17. Persistent 
inflammation in RA and periodontitis has been associated with other comorbidities, for example cardiovascular 
disease (CVD)18,19.
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Mitochondrial dysfunction has been linked to numerous diseases including RA, periodontitis, neurodegen-
erative diseases, diabetes, cancer, and  obesity20–24. Mitochondria have a central role in energy utilization and 
energy production by regulating cellular bioenergetics and metabolism and the generation of  ROS25. Defective or 
insufficient mitochondrial function at the cellular level is thought to impact whole-body metabolic  homeostasis26. 
During inflammatory response, innate immune cells such as polymorphonuclear leukocytes (PMN) and mac-
rophages have the potential to extensively increase ongoing metabolism and enhance the metabolic demand for 
oxygen beyond the capacity of the existing  resources27. Consequently, hypoxia arises, causing reduced mito-
chondrial respiration and finally resulting in excessive production of ROS and mitochondrial DNA  damage28,29.
The assessment of metabolic changes in diseases has been used to investigate overall metabolic activity. Meta-
bolic profiling of patients with established RA has proven to be significantly different from healthy  controls30. 
Quantitative abnormalities in blood FA and lipids have been found in RA and  periodontitis30–35.
The naturally occurring amino acid derivative l-carnitine (levocarnitine, LC) is required to transfer medium- 
and long-chain FA across the inner mitochondrial membrane for subsequent β-oxidation. The plasma acetylcar-
nitine (AC2) level is influenced by inhibitors to FA oxidation in  mice36. Increased acylcarnitine (AC) concentra-
tion has been linked to the progression of several chronic diseases, including insulin resistance and  CVD37,38. 
LC is also found to serve as precursor for the generation of trimethylamine-N-oxide (TMAO) via a multistep 
metaorganismal gut microbiota-dependent  pathway39 (Fig. 1A). TMAO is recognized to induce inflammation and 
to interfere with cholesterol metabolism. Elevated TMAO concentrations were found to be both proatherogenic 
and associated with CVD  risks40.
Figure 1.  (a) Overview of fatty acid oxidation, carnitine biosynthesis and metabolism, and TMAO formation. 
(b) Relationship between serum carnitine- and choline derivatives in RA patients with different periodontal 
conditions (N = 78). CPT, carnitine palmitoyl-transferase; CACT, carnitine-acylcarnitine translocase; TML, 
trimethyl lysine; GBB. γ-butyrobetaine; TMA, trimethylamine; TMAO, trimethylamine N-oxide.
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The mechanisms behind a possible link between RA and periodontal disease are still not adequately elu-
cidated. Detailed knowledge about the shared inflammatory processes will increase the understanding of the 
biological mechanisms behind the association. Therefore, the aim of this study was to explore whole-blood FA, 
serum lipid composition, carnitine- and choline derivatives including TMAO in RA patients with different 
degrees of periodontal inflammation to reveal any variations in RA disease activity status and periodontitis 
severity.
Material and methods
Study design. The data for this cross-sectional study were collected between May 2013 and March 2016 at 
the Department of Rheumatology, Haukeland University Hospital, Bergen, and Department of Clinical Den-
tistry, University of Bergen, Norway. Study protocol and informed consent, according to the Helsinki Declara-
tion of 1975, version  200841, were approved by the Regional Committee for Medical and Health Research Ethics 
(REC, Health Region West) (2012/2212), University of Bergen, Norway. All participants read and signed the 
written informed consent.
Study population. In this study, RA outpatients with chronic established RA were invited to participate. 
RA disease was classified using the 2010 classification criteria of American College of Rheumatology/Euro-
pean League Against Rheumatism (ACR/EULAR)42. Inclusion criteria were chronic established RA, Caucasian 
ethnicity and ≥ 35 years of age. The criteria for exclusion were diabetes, malignancy, pregnancy, breastfeeding, 
and antibiotic use within 3 months prior to the study. Demographic and behavioral characteristics were col-
lected using questionnaires. Past medical history, clinical and laboratory data on RA status and medication were 
obtained from medical records. RA patients were examined intra-orally and periodontal data were collected 
under standardized conditions by a single calibrated dentist (KB). A detailed description is provided in Beyer 
et al.  201843.
In brief, patient-related data including RA disease debut and duration, modified health assessment question-
naire (MHAQ)44, RA disease activity score (DAS28-ESR)45,46, joint damage, and patient global health assessment 
scored on a visual analogue scale (VAS)47 were obtained. Routine laboratory analyses included erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF) and anti-citrullinated protein antibody 
(ACPA). Active RA was defined as DAS28 ≥ 2.6 and RA disease in remission as DAS28 < 2.648.
A comprehensive periodontal examination including registration of pocket depth (PD), clinical attachment 
level (CAL), bleeding on probing (BoP) and accumulation of dental plaque (PI) at six sites per tooth was assessed. 
A detailed description of periodontal measurements is provided in Beyer et al.49. The patients were asked not to 
eat, drink and smoke for at least two hours prior to examination.
The assessment of periodontal status was adapted from the Centers for Disease Control (CDC)/American 
Academy of Periodontology (AAP) clinical case  definitions50. Subjects were classified into three sub-groups: (1) 
gingivitis: PD ≤ 3 mm and BoP, (2) mild/moderate periodontitis: ≥ 2 interproximal sites with CAL 3–5 mm (not 
on the same tooth) or ≥ 2 interproximal sites with PD ≥ 4 mm (not on the same tooth) and BoP, or (3) severe 
periodontitis: ≥ 2 interproximal sites with CAL ≥ 6 mm (not on the same tooth) and ≥ 1 interproximal site with 
PD ≥ 5 mm and BoP.
Furthermore, subjects with measurements of CAL ≤ 5 mm, and CAL > 5 mm at least at two tooth sites were 
assigned into two separate groups.
Current smokers were defined as subjects who smoked or stopped smoking less than 12 months prior to study 
enrollment. Former smokers were subjects who quit smoking more than 12 months ago.
Peripheral venous blood samples were obtained by venipuncture at the antecubital fossa (Vacutainer Blood 
Collection Set, BD Vacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ, USA) using 3 mL K2EDTA 
Vacuettes and Serum Sep Clot Activator vacutainers (Greiner Bio-One Gmbh, Kremsmuenster, Austria). Whole 
blood samples for FA analysis were kept on ice, frozen at  − 20 °C (within 30 min) for 24 h, then stored at  − 80 °C 
until analysis. Whole blood samples used for serum extraction were set to coagulate for minimum 30 min (maxi-
mum 60 min). After centrifugation at 1300× g for 10 min, the supernatant was stored at − 80 °C until analysis.
Analysis of fatty acids by gas chromatography. Whole blood content and composition of 38 FA 
were analysed at the Institute of Marine Research (IMR), Bergen, Norway using ultrafast gas chromatography 
(UFGC) (Thermo Electron Corporation, Massachusetts, USA)51 as an accredited laboratory method (NS-EN 
ISO/IEC 17025). The FA composition was calculated using an integrator (Chromeleon 6.80, Dionex Corpora-
tion, California, USA) connected to the  UFGC52. A standard mixture of methyl esters (Nu-Chek, Minnesota, 
USA) was used to ascertain the identification of FA. The responsiveness of the detector was routinely checked 
against the composition of a commercial mixture of FAME standards.
The absolute and relative concentrations of whole blood tissue FA were expressed as mg FA/g sample (wet 
weight) and as weight percentage (wt%) of total FA methyl esters (FAME), respectively. The detection limit was 
0.003 mg FA/g sample, and the limit of quantification (LOQ) was 0.01 mg FA/g samples. FA below LOQ were 
excluded from the analysis in all patients. The concentrations of identified and unidentified FA were summed up 
to the total amount of measured FA. For FA profile data analysis, the relative concentration of each FA (wt%) over 
the sum of all FA (mg/g) was calculated. FA were described by their lipid structure using the C:Dn−x nomencla-
ture. Common FA names have been enclosed for more convenient identification. FA were divided according to 
their chemical classification into saturated FA (SFA), monounsaturated FA (MUFA), polyunsaturated FA (PUFA), 
and sum n−3 and n−6 PUFA. Further, the following ratios and indices were calculated in wt%: n−3/n−6, AA/EPA, 
AA/LA, EPA/ALA, omega-3 index (EPA + DHA), anti-inflammatory fatty acid (AIFA) index [(EPA + dihomo-
gamma-linolenic acid (DGLA) + DHA + DPA)/AA)*100), and de novo lipogenesis (DNL) index (C16:0/LA). 
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Omega-3 index data were categorized into tertiles (lowest, middle, and highest tertile). Additionally, desaturase 
and elongase (Elo) activity indices have been calculated as percentages of individual FA product/precursor ratio: 
Elo activity from C16:0 to C18:0: C18:0/C16:0; Δ5-desaturase (D5D) for n−6 FA: AA/DGLA. D5D for n−3 FA 
was not evaluated since the LOQ for stearidonic acid (SDA) was reached in only five patients.
Analysis of serum lipids. Serum lipid samples were measured enzymatically on a Hitachi 917 system 
(Roche Diagnostics GmbH, Mannheim, Germany) using the triacylglycerol (TG; GPO-PAP), cholesterol 
(CHOD-PAP), high density lipoprotein cholesterol (HDL-C)/low-density lipoprotein cholesterol (LDL-C) plus 
kits from Roche Diagnostics. The non-esterified FA (NEFA) and phospholipids (PL) were measured using the 
NEFA FS kit and Phospholipids FS kit from Diagnostic Systems GmbH (Holzheim, Germany), respectively. 
The results are expressed as mmol/L sample. The following ratios and indices have been calculated: HDL-C/
LDL-C, Non-HDL-C [total cholesterol (TC) minus HDL-C], Castelli`s risk index (TC/HDL-C)53 and athero-
genic index [log10(triglyceride, TG)/HDL-C]54. Cut-offs for dyslipidemia were set as follows: TG > 2.6 mmol/L; 
TC > 6 mmol/L; HDL-C < 1 mmol/L or LDL-C > 4 mmol/L.
Analysis of serum carnitine‑ and choline derivative. Serum choline, betaine, trimethyl lysine (TML), 
γ-butyrobetaine (GBB) and TMAO, as well as free l-carnitine and seven AC were analyzed using liquid chro-
matography-tandem-mass spectrometry (LC–MS/MS)55,56. The following AC grouped by chain length were 
measured: the short chain (SC)-AC: AC2, propionylcarnitine (AC3), iso-/L-valerylcarnitine (AC5); the MC-AC: 
octanoylcarnitine (AC8), lauroylcarnitine (AC12); and the LC-AC, including myristoylcarnitine (AC14) and 
palmitoylcarnitine (AC16). The concentration of the serum metabolites is expressed in µ M. The following acyl-
carnitine ratios AC2/AC8, AC2/AC12, AC2/AC14, AC2/AC16, were calculated. Further, TMAO values were 
categorized into percentiles (lowest and highest percentile).
Statistical analyses. Statistical analyses were performed using Stata SE 15.0 for Microsoft Windows 
(Stata Corp LP, Texas, USA). Graphs were designed with GraphPad Prism 7, version 7.04 for Microsoft Win-
dows (GraphPad Software, La Jolla, California, USA). All continuous and categorical data were expressed as 
mean ± standard deviation and as number (percentage) of patients respectively, if not explicit stated differently.
Continuous numeric outcomes were tested for logarithmic (log) normality. Since no statistically relevant 
differences were found between log- and non-log transformed data, statistical analyses were conducted on non-
log transformed data using Person chi-square, Student t-test and one-way analysis of variance (ANOVA). In the 
ANOVA, Scheffe`s post hoc test was conducted to determine possible group differences. Pearson’s correlation 
coefficient was used to measure the statistical relationship between selected continuous variables. A P-value less 
than 0.05 was considered statistically significant.
Results
The study population consisted of RA patients (N = 78, 73% females) aged 57 ± 12 years with different degrees 
of periodontal inflammation. The sociodemographic and clinical characteristics of the study population are 
described in detail in Table 1, and Beyer et al.43,49. Further patient characteristics have been described and 
categorized by prednisolone medication in Supplementary Table S3, by periodontal status in Supplementary 
Table S4, and CAL in Supplementary Table S5.
Active RA was diagnosed in 58% of the patients. Erosive destruction of cartilage and bone and seropositivity 
against RF and/or ACPAs were not related to RA disease activity (DAS28). Current treatment with conventional 
disease-modifying antirheumatic drugs (c-DMARDs) was registered in 42%, biological DMARDs (b-DMARDs) 
in 14%, and c- and b-DMARDs in 39% of the patients, and 27% of the patients were treated with prednisolone. 
DAS28, VAS, MHAQ and the inflammation markers ESR and CRP varied significantly between active RA and 
RA disease in remission, whereas age, BMI, smoking status, periodontal conditions, or treatment mode with 
c- and/or b-DMARDs did not differ. Periodontal examination revealed severe periodontitis in 18% of the indi-
viduals, 64% had mild or moderate periodontitis and 18% were diagnosed with gingivitis. Eighteen percent of 
the patients were current smokers, whereas 47% were former smokers.
Evaluation of whole blood fatty acid and serum lipid profiles. Of the measured FA, 24 reached 
LOQ and were included into the analysis. The distribution and absolute FA concentration described as median 
and range are presented in Supplementary Table S1. The FA composition has been visualized in Fig. 2A grouped 
by RA disease status. The predominant FA species were C16:0 and C18:0 among SFA, C18:1 and C16:1 among 
MUFA, LA and AA among n−6 PUFA, and DHA, EPA and DPA among n−3 PUFA. Of lipids, TC, TG, HDL-C, 
LDL-C, NEFA and PL including the corresponding ratios and indices were analyzed.
Assessment of fatty acid and lipid composition in relation to RA disease activity, predniso‑
lone medication and periodontitis severity. The total FA concentration was higher in patients with 
active RA compared with patients in RA remission (P = 0.047) (Fig. 2b, Supplementary Table S2). Likewise, RA 
patients with prednisolone treatment had higher total FA concentrations compared to those without predniso-
lone (P = 0.043) (Fig. 3, Supplementary Table S3). In regard to periodontal status, the total FA concentration was 
highest in gingivitis and lowest in mild/moderate periodontitis (Fig. 4a, Supplementary Table S4). Allocating 
RA patients by CAL ≤ 5 mm and CAL > 5 mm, the FA profiles did not show any significant differences (Sup-
plementary Table  S5). None of the main FA classes categorized by their chemical classification as SFA, MUFA, 
PUFA differed for any of the aforementioned grouping variables. Although several individual FA varied with 
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for RA disease activity status (Fig. 2b, Supplementary Table S2), prednisolone treatment (Fig. 3, Supplementary 
Table S3) or periodontal status (Fig. 4a, Supplementary Table S4), solely C15:0 was positively associated with 
CRP (P < 0.01, R = 0.30).
Assessment of the lipid concentrations, TG, TC, HDL-C, LDL-C and PL revealed no relation to RA disease 
activity status (Supplementary Table S2). RA patients taking prednisolone had a higher PL concentration com-
pared to no prednisolone (P = 0.015) (Fig. 3, Supplementary Table S3). TC and HDL-C showed a slightly, but not 
significant, higher concentration related to prednisolone use (Supplementary Table S3).
Regarding periodontal inflammation, TG was lowest in patients with mild/moderate periodontitis and highest 
in patients with gingivitis. Additionally, the most unfavorable atherogenic index was found in RA patients with 
mild/moderate periodontitis (Fig. 4a, Supplementary Table S4). Increased CAL > 5 mm was related to a lower 
concentration of HDL-C (P = 0.048) and a more unfavorable Castelli`s risk index compared to CAL ≤ 5 mm 
(Fig. 4b, Supplementary Table S5). Interestingly, evaluating dyslipidemia, a more than twice as high percentage 
of active RA patients (42.2%) had a TC concentration > 6 mmol/L compared to RA patients in remission (18.2%, 
P = 0.025). However, despite elevated TC concentrations in approximately one third of the RA patients, elevated 
LDL-C and decreased HDL-C concentrations were found in only 19.2% and 6.4% of the patients, respectively.
Table 1.  Patient characteristics grouped by rheumatoid arthritis (RA) disease activity (DAS 28). Categorical/
continuous variables of demographic, behavioral and clinical characteristics. RA disease activity, measured 
as disease activity score 28 (DAS28); Remission, RA disease in remission defined as DAS28 ≤ 2.6; Active RA 
disease defined as DAS28 > 2.6; N, number; Age, patient’s age in years at the time of clinical examination; BMI 
body mass index, PD probing depth, CAL clinical attachment level, BoP bleeding on probing, PI plaque index, 
DAS28 disease activity score 28, VAS patient global health assessment score on a visual analogue scale, MHAQ 
modified health assessment questionnaire, RF, ACPA, seropositivity, positive tests for rheumatoid factor (RF) 
(N = 74) and/or anti-citrullinated protein antibody (ACPA) (N = 77); ESR erythrocyte sedimentation rate, CRP 
C-reactive protein, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C 
low-density lipoprotein cholesterol. Analysed with Pearson chi-square and Student t-test: P-level < 0.05. *n = 74.
Total N = 78 RA remission N = 33 Active RA N = 45 P value
Females (N/%) 57/73 24/73 33/73 0.95
Age (years) 57 ± 12 57 ± 12 58 ± 12 0.70
BMI (kg/m2) 26.1 ± 4.3 25.9 ± 4.4 26.3 ± 4.4 0.67
Smoking status (N/%)
Never smokers 29/37 12/36 17/38
0.74Former smokers 35/45 17/52 18/40
Current smokers 14/19 4/12 8/22
Oral data
Number of teeth 25 ± 5 25 ± 4 24 ± 6 0.22
PD (mm) 2.8 ± 0.4 2.7 ± 0.3 2.8 ± 0.4 0.65
CAL (mm) 3.1 ± 0.8 3.0 ± 0.7 3.1 ± 0.8 0.57
BoP (% of sites) 31 ± 16 33 ± 14 30 ± 17 0.49
PI (% of sites) 33 ± 16 36 ± 19 31 ± 14 0.20
Periodontitis (N/%)
No 14/18 5/15 9/20
0.68Mild/moderate 50/64 23/70 27/60
Severe 14/18 5/15 9/20
RA data
RA debut (age) 43 ± 14 41 ± 13 45 ± 15 0.30
RA duration (years) 15 ± 11 16 ± 12 14 ± 11 0.29
DAS28 (score) 3.0 ± 1.1 2.1 ± 0.3 3.7 ± 1.0  < 0.001
VAS (score) 28 ± 21 17 ± 14 36 ± 21  < 0.001
MHAQ (score) 0.37 ± 0.38 0.17 ± 0.25 0.52 ± 0.39  < 0.001
RF, ACPA (N/%) 60/77 28/85 32/71 0.16
Laboratory data
ESR (mm/hr) 19.8 ± 15.5 12.7 ± 8.3 25.0 ± 17.5  < 0.001
CRP (mg/L) 8.8 ± 13.5 5.0 ± 10.0 11.6 ± 15.1 0.031
RF (IU/ml)* 184 ± 385 175 ± 364 190 ± 405 0.87
TG (mmol/L) 1.20 ± 0.82 1.12 ± 0.65 1.26 ± 0.92 0.43
TC (mmol/L) 5.52 ± 1.22 5.33 ± 1.02 5.64 ± 1.34 0.26
HDL-C (mmol/L) 1.64 ± 0.50 1.57 ± 0.44 1.69 ± 0.53 0.30
LDL-C (mmol/L) 3.29 ± 0.93 3.24 ± 0.76 3.33 ± 1.05 0.69
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Figure 2.  Association between whole blood FA, serum lipids, serum carnitine- and choline derivatives and 
RA disease activity. (a) Columns show relative FA concentrations (mean ± SD) grouped by RA disease activity, 
DAS28 score ≤ 2.6 = RA in remission (N = 33, coloured in blue) or DAS28 ≥ 2.6 = active RA (N = 45, coloured in 
red) and by chemical classification (SFA, MUFA, PUFA n−6, PUFA n−3) sorted from high to low abundance. 
(b) Boxplots show FA, lipids, and carnitine- and choline derivatives significant associated with RA disease 
activity status (RA in remission (N = 33, coloured in blue, active RA (N = 45, coloured in red). The boxplots 
show medians, the error bars indicate 5–95% confidence interval. The connectors show statistically significant 
differences, P < 0.05. P values are based on Student t-test.
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Fatty acid and lipid profiles in relation to smoking status. The concentrations of n-3 PUFA, n-3/n-
6, EPA, DHA, omega-3 index, AIFA increased from current, to former, to never smokers, whereas the concentra-
tion of AdA decreased. AA/EPA concentration was lowest in never smokers, elevated in former smokers and was 
most unfavorable in current smokers (Fig. 5, Supplementary Table S6). Lipid parameters did not differ within 
smoking status (Supplementary Table S6).
Assessment of serum carnitine‑ and choline derivatives including trimethylamine 
N‑oxide. Performing Pearson’s correlation, the following serum metabolites were associated: l-carnitine cor-
related with GBB and choline; betaine correlated with GBB, choline and TML; GBB correlated with choline and 
TML; choline correlated with TML; and TML correlated with TMAO (Fig. 1b). Choline as precursor of phos-
phatidylcholine, a major constituent of cell membranes, was negative correlated with PL (R =  − 0.26, P < 0.020). 
Additionally, as part of the structural components of lipoproteins, choline correlated negatively with HDL-C 
(R =  − 0.38, P < 0.001). Choline and betaine also correlated with CRP (R = 0.26, P = 0.020 and R = 0.29, P = 0.011, 
respectively), whereas none of the other serum metabolites reached the level of significance.
Serum acylcarnitine profiles in relation to RA disease activity status and prednisolone treat‑
ment and periodontitis severity. Serum concentrations of the acylcarnitines AC8 and AC12 were higher 
in active RA compared to RA in remission (Fig. 2b, Supplementary Table S2). RA patients with prednisolone 
medication had lower AC2 concentrations compared to those without prednisolone (Fig.  3, Supplementary 
Table S3). Of the acylcarnitine ratios, the AC2/AC12 and AC2/AC14 decreased in patients with prednisolone 
medication compared to no prednisolone (Fig. 3, Supplementary Table S3). AC12 was positively related to CRP 
(P = 0.027, R = 0.25). Further, AC3 was highest in severe periodontitis and lowest in the mild/moderate peri-
odontitis group (Fig. 4a, Supplementary Table S4).
Figure 3.  Association between whole blood FA, serum lipids, serum carnitine- and choline derivatives 
and prednisolone medication in RA patients (N = 78). Boxplots show FA, lipids, and carnitine- and choline 
derivatives significant associated with intake of prednisolone (no prednisolone, N = 57, coloured in blue; 
prednisolone medication, N = 21, coloured in red). P values are based on Student t-test. The boxplots show 
medians, the error bars indicate 5–95% confidence interval. The connectors show statistically significant 
differences, P < 0.05. P values are based on Student t-test.
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Serum carnitine‑ and choline derivatives in relation to RA disease activity, prednisolone medi‑
cation and periodontitis severity. l-carnitine, choline, betaine, GBB, and TML did not differ for RA 
disease activity status (Supplementary Table  S2). However, RA patients with prednisolone medication com-
pared with no prednisolone had lower concentrations of l-carnitine, choline and GBB (Fig. 3, Supplementary 
Table S3). Aggravating periodontal inflammation was related to increased betaine and choline concentrations 
(Supplementary Table  S4). RA patients with CAL > 5  mm had higher concentration of l-carnitine, choline, 
betaine and TML compared to patients with CAL ≤ 5 mm (Fig. 4b, Supplementary Table S5).
Figure 4.  Association between whole blood FA, serum lipids, serum carnitine- and choline derivatives and 
periodontal conditions in RA patients (N = 78). (a) Boxplots show FA, lipids, and carnitine- and choline 
derivatives significant associated with the diagnosis of periodontal disease, grouped by severity: group 
1 = gingivitis (N = 14, coloured in red), group 2 = mild/moderate periodontitis (N = 50, coloured in blue), group 
3 = severe periodontitis (N = 14, coloured in black). P-values are based on ANOVA. The boxplots show medians, 
the error bars indicate 5–95% confidence interval. The connectors show statistically significant differences 
within these groups, P < 0.05). (b) Boxplots show lipids and carnitine- and choline derivatives significant 
associated with measurements of clinical attachment level, grouped by CAL ≤ 5 mm (N = 50, coloured in 
red) and CAL > 5 mm (N = 28, coloured in blue). The boxplots show medians, the error bars indicate 5–95% 
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Assessment of trimethylamine N‑oxide. TMAO concentration did not show significant differences for 
RA disease activity (Supplementary Table S2), prednisolone medication (Supplementary Table S3), periodontal 
diagnosis (Supplementary Table S4), CAL (Supplementary Table S5) or smoking (Supplementary Table S6). Cat-
egorizing TMAO into percentiles, in the highest percentile, the sum of PUFA, LA, the serum metabolites GBB 
and TML were increased, whereas AA/EPA and C18:1 were decreased, compared to the lowest percentile (Fig. 6, 
Supplementary Table S7). Categorizing TMAO levels by omega-3 tertiles, the highest TMAO concentration was 
about twofold higher in the 3rd (4.57 ± 4.06 µM) compared to the 1st tertile (10.18 ± 12.16 µM, P = 0.015) (Sup-
plementary Table S8).
Smoking was not related to any changes in acylcarnitine, carnitine- and choline derivatives or TMAO (Sup-
plementary Table S6).
Discussion
This cross-sectional study shows a statistically significant relation between abnormal elevated TC in active RA 
compared to TC levels in RA remission. This conflicts with some former studies reporting reduced TC con-
centration in relation to active RA  disease57–59. In liver mitochondria, cholesterol accumulation has been found 
to disrupt mitochondrial functional performance which can contribute to oxidative stress and organ  injury60. 
Figure 5.  Association between whole blood FA and smoking status in RA patients (N = 78). Boxplots show FA, 
FA indices and -ratios significant associated with smoking status: group 1 = never smokers (N = 29, coloured in 
red), group 2 = former smokers (N = 35, coloured in blue), group 3 = current smokers (N = 14, coloured in black). 
The boxplots show medians, the error bars indicate 5–95% confidence interval. The connectors show statistically 
significant differences within these groups, P < 0.05. P-values are based on ANOVA.
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Similarly, cultured macrophages of advanced atherosclerotic lesions are found to progressively accumulate TC, 
which stimulates PL biosynthesis as a response to protect the macrophages from TC-cytotoxicity. A prolongated 
cholesterol load has been related to mitochondrial dysfunction and cellular  apoptosis61. Further, more recent 
evidence indicates that mitochondrial cholesterol-load influence mitochondrial function in several neurological 
diseases such as Alzheimer’s  disease62.
Serum PL concentration was significantly higher in RA patients taking prednisolone medication compared 
to no prednisolone. Our finding is comparable to results of a more recent study of PL classes that observed 
higher total PL in synovial fluid of RA patients compared to  controls63. Similarly, the total FA concentration was 
significantly higher in active RA compared to RA in remission and in patients taking prednisolone compared to 
no prednisolone medication. Elevated FA concentration in blood is known to increase inflammatory  processes64 
and to be increased by  inflammation65. However, except for some specific FA, neither the main FA classes nor 
AIFA or DNL index were found to differ. Additionally, the analysis of serum AC revealed a higher concentration 
of the MC-AC in patients with active RA, and a decrease in some AC2 to MC-AC and LC-AC ratios in those of 
the RA patients taking prednisolone medication. Furthermore, AC12 was also found positively correlated with 
CRP. AC are generally considered the transport form of FA (C2-C26)66. Accumulation of toxic lipid product 
intermediates, including MC- and LC-AC have been suggested as an indicator for inefficient LC-FAO. FAO 
inhibition is known as a characteristic in mitochondrial  dysfunction67.
Interestingly, the metabolite choline was negatively correlated to PL in RA patients taking prednisolone medi-
cation compared to no prednisolone. Equally to in our study, others found choline to correlate with CRP in RA 
 patients30. In a study on RA fibroblast-like synoviocytes, under inflammatory conditions, an activation of choline 
metabolism and alteration of phospholipid metabolism have been  suggested68. Choline is considered essential 
for the biosynthesis of  PL69, therefore an increased PL turnover in neurodegenerative diseases like Alzheimer’s 
disease has been postulated responsible for the decrease of choline  concentration70.
Notably, the highest concentrations of choline and its metabolite, betaine, were found in RA patients with 
severe periodontitis or CAL > 5 mm. Circulating levels of high choline and low betaine concentrations have been 
associated with an unfavourable cardiovascular risk factor profile in healthy individuals from the Hordaland 
Health Study (HUSK) in  Norway71. The HUSK study also found a positive relationship between choline and TG, 
and BMI. We could not find any relationship between choline and TG, or BMI (results not shown) but found 
a robust negative relationship between choline and HDL-C. HDL-C was found at a lower concentration in RA 
patients with CAL > 5 mm compared to lower CAL. Of note, in a more recent study on cerebrovascular disease 
in older adults, higher plasma choline concentrations were associated with a favourable cardiometabolic risk-
factor profile, like elevated HDL-concentration72.
Choline, or more specifically the microbial metabolism of phosphatidylcholine, has been given much atten-
tion due to the production of the pro-atherosclerotic metabolite TMAO (Fig. 1a)73. Additionally, l-carnitine 
serve as precursor for the generation of TMAO (Fig. 1a)40. TML and GBB are also known as biosynthetic inter-
mediates in l-carnitine  synthesis74. In our study, choline, betaine and GBB correlated significantly with TMAO. 
In humans, TMAO is known to accumulate through the consumption of TMAO-containing  seafood75. The 
Figure 6.  Association between whole blood FA, serum carnitine- and choline derivatives, and TMAO 
percentiles in RA patients (N = 78). Boxplots show FA and carnitine- and choline derivatives significant 
associated with TMAO percentiles, categorized into lowest TMAO percentile: percentile 1 (0.67–4.21 µM, 
N = 39, coloured in red) and highest TMAO percentile: percentile 2 (4.29–44.28 µM, N = 39, coloured in blue). 
The boxplots show medians, the error bars indicate 5–95% confidence interval. The connectors show statistically 
significant differences, P < 0.05. P-values are based on Student t-test.
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TMAO concentration in our study correlated positively to whole blood omega-3 index. Recently published data 
from our group of RA patients revealed a positive relation between marine omega-3 intake and whole blood 
omega-3  index43. Grouping RA patients into TMAO percentiles, the l-carnitine intermediates TML and GBB 
were elevated in the highest TMAO percentile. CRP and ESR were higher in the second TMAO percentile but 
did not reach level of significance. Despite differences in several serum carnitine- and choline derivative, TMAO 
was not related to RA or periodontal disease related variables. Research data covering the causal link between 
TMAO and other inflammatory diseases like CVD are  contradicting76. The results of our study seem to reflect 
the conflicting findings of other studies and further research is needed to establish the role of TMAO in health 
and disease in humans.
Variables that may potentially affect data interpretation such as age, gender, BMI, smoking status, RA onset, 
RA duration, periodontal measurements and diagnosis were analysed post recruitment and no statistically 
significant relations to RA disease activity were found.
However, age, gender, BMI, but also diet- and physical activity dependent differences in FA and lipid com-
position are well documented  findings77,78, which should be taken into consideration for the generalizability 
of the results. RA patients of this study were recruited at a university hospital based rheumatologic outpatient 
clinic. The overall RA disease activity score in this study measured by DAS28 was at the lower range and may 
reflect an effective treat-to-target treatment regime with good access to synthetic and biologic disease modify-
ing anti-rheumatic drugs (respectively s-DMARDs and b-DMARDs). Another point of discussion could be the 
patient-related perceived ability to pass through the examinations that may have influenced the patient’s decision 
to participate in the study, and finally resulted in refusal by patients with more severe RA. Furthermore, using 
DAS28 score to define RA disease remission means allowing for some degree of residual disease activity. This is 
also true in this study, as patients with RA in remission showed CRP and ESR levels exceeding the physiologi-
cal range. Choosing remission cutoff point < 2.6 would reduce, but not exclude, the number of patients with 
residual disease  activity79. A DAS28-based definition of remission may therefore be a shortcoming, and more 
recent guidance documents for RA clinical trials recommendation of the European Medicines Agency and the 
FDA refer to DAS28 < 2.6 as ‘low disease activity’80. Emphasizing awareness, DAS28 score is a well-established 
and validated tool, especially in clinical studies.
RA treatment with a combination of s-DMARDs and b-DMARDs is currently medical standard. Therefore, 
limiting patient recruitment to one group of DMARDs is not feasible as it will result in a non-representative 
patient selection. Furthermore, no differences between active RA and RA in remission were found when grouping 
RA medication by no, s- and/or b-DMARDs43. Prednisolone was significantly related to active RA, but not to 
periodontal measurements. Glucocorticoids like prednisolone are efficiently used in RA treatment due to their 
anti-inflammatory and immunosuppressive effects but are also associated with adverse effects depending on 
several factors like mean and cumulative dose, route of administration, and patient-specific  factors81. However, 
adverse effects to low-dose glucocorticoids, as administrated in most RA patients of this study, are less  frequent82.
Regarding the common effect of smoking on periodontitis, we reported previously higher mean PD 
(2.9 ± 0.4 mm) and mean CAL (3.2 ± 0.9 mm) in ever smokers compared to never smokers (PD 2.6 ± 0.2 mm, 
P = 0.002 and CAL 2.8 ± 0.3 mm, P = 0.015). Males categorized as ever smokers were found to have the highest 
mean PD (3.2 ± 0.6 mm) and CAL (4.0 ± 1.4 mm). Further, male sex and smoking were associated with fewer 
teeth (P < 0.001), and more dental plaque (P = 0.017) compared to female sex in ever smokers. Between former 
and current smokers, no differences were  found43.
In this study, the observed metabolic alterations were related to RA disease activity and prednisolone medi-
cation that both were further related to increased CRP. Different degrees of periodontal inflammation in this 
group of RA patients could not be related to CRP. It can be speculated that the additional inflammatory burden 
caused by periodontal disease is not able to increase the already elevated inflammatory state caused by RA. 
Furthermore, RA patients of this study were recruited from urban catchment with good access to dental care 
(results not shown), and oral health is found improving continuously over the last  decades83.
The findings of this study should be interpreted with caution within the limits for generalizability and study 
conceptualization. The influence of periodontal inflammation on the observed metabolic variations was limited, 
but not absent. Nevertheless, our findings may support the need for interdisciplinary collaboration within the 
field of medicine and dentistry in patient stratification to improve personalized treatment. Longitudinal studies 
are warranted to further assess the potential impact of mitochondrial function on RA and periodontitis.
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